David B Dix1, Conrad V Fernandez2, Yueh-Yun Chi3, Elizabeth A Mullen4, James I Geller5, Eric J Gratias6, Geetika Khanna7, John A Kalapurakal8, Elizabeth J Perlman9, Nita L Seibel10, Peter F Ehrlich11, Marcio Malogolowkin12, James Anderson13, Julie Gastier-Foster14, Robert C Shamberger15, Yeonil Kim3, Paul E Grundy16, Jeffrey S Dome17. 1. British Columbia Children's Hospital, Vancouver, British Columbia, Canada. 2. Dalhousie University, Halifax, Nova Scotia, Canada. 3. University of Florida, Gainesville, FL. 4. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA. 5. Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 6. University of Tennessee College of Medicine Chattanooga, Chattanooga, TN. 7. Washington University School of Medicine, St Louis, MO. 8. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. 9. Ann and Robert H. Lurie Children's Hospital, Chicago, IL. 10. National Cancer Institute, Bethesda, MD. 11. University of Michigan, Ann Arbor, MI. 12. University of California at Davis Comprehensive Cancer Center, Sacramento, CA. 13. Merck Research Laboratories, North Wales, PA. 14. Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. 15. Boston Children's Hospital and Harvard Medical School, Boston, MA. 16. Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada. 17. Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
PURPOSE: In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533/AREN0532 studies assessed whether augmenting therapy improved event-free survival (EFS) for these patients. Patients with stage I/II disease received regimen DD4A (vincristine, dactinomycin and doxorubicin) but no radiation therapy. Patients with stage III/IV disease received regimen M (vincristine, dactinomycin, and doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy. METHODS: Patients were enrolled through the AREN03B2 Biology study between October 2006 and October 2013; all underwent central review of pathology, surgical reports, and imaging. Tumors were evaluated for LOH1p/16q by microsatellite testing. EFS and overall survival were compared using the log-rank test between NWTS-5 and current studies. RESULTS: LOH1p/16q was detected in 49 of 1,147 evaluable patients with stage I/II disease (4.27%) enrolled in AREN03B2; 32 enrolled in AREN0532. LOH1p/16q was detected in 82 of 1,364 evaluable patients with stage III/IV disease (6.01%) in AREN03B2; 51 enrolled in AREN0533. Median follow-up for 83 eligible patients enrolled in AREN0532/0533 was 5.73 years (range, 2.84 to 9.63 years). The 4-year EFS for patients with stage I/II and stage III/IV disease with LOH1p/16 was 87.3% (95% CI, 75.1% to 99.5%) and 90.2% (95% CI, 81.8% to 98.6%), respectively. These results are improved compared with the NWTS-5 updated 4-year EFS of 68.8% for patients with stage I/II disease (P = .042), and 61.3% for patients with stage III/IV disease (P = .001), with trends toward improved 4-year overall survival. The most common grade 3 or higher nonhematologic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%). CONCLUSION: Augmentation of therapy improved EFS for patients with favorable histology Wilms tumor and LOH1p/16q compared with the historical NWTS-5 comparison group, with an expected toxicity profile.
PURPOSE: In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533/AREN0532 studies assessed whether augmenting therapy improved event-free survival (EFS) for these patients. Patients with stage I/II disease received regimen DD4A (vincristine, dactinomycin and doxorubicin) but no radiation therapy. Patients with stage III/IV disease received regimen M (vincristine, dactinomycin, and doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy. METHODS:Patients were enrolled through the AREN03B2 Biology study between October 2006 and October 2013; all underwent central review of pathology, surgical reports, and imaging. Tumors were evaluated for LOH1p/16q by microsatellite testing. EFS and overall survival were compared using the log-rank test between NWTS-5 and current studies. RESULTS: LOH1p/16q was detected in 49 of 1,147 evaluable patients with stage I/II disease (4.27%) enrolled in AREN03B2; 32 enrolled in AREN0532. LOH1p/16q was detected in 82 of 1,364 evaluable patients with stage III/IV disease (6.01%) in AREN03B2; 51 enrolled in AREN0533. Median follow-up for 83 eligible patients enrolled in AREN0532/0533 was 5.73 years (range, 2.84 to 9.63 years). The 4-year EFS for patients with stage I/II and stage III/IV disease with LOH1p/16 was 87.3% (95% CI, 75.1% to 99.5%) and 90.2% (95% CI, 81.8% to 98.6%), respectively. These results are improved compared with the NWTS-5 updated 4-year EFS of 68.8% for patients with stage I/II disease (P = .042), and 61.3% for patients with stage III/IV disease (P = .001), with trends toward improved 4-year overall survival. The most common grade 3 or higher nonhematologic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%). CONCLUSION: Augmentation of therapy improved EFS for patients with favorable histology Wilms tumor and LOH1p/16q compared with the historical NWTS-5 comparison group, with an expected toxicity profile.
Authors: Eric J Gratias; Jeffrey S Dome; Lawrence J Jennings; Yueh-Yun Chi; Jing Tian; James Anderson; Paul Grundy; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Elizabeth J Perlman Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Daniel M Green; Wei Liu; William H Kutteh; Raymond W Ke; Kyla C Shelton; Charles A Sklar; Wassim Chemaitilly; Ching-Hon Pui; James L Klosky; Sheri L Spunt; Monika L Metzger; DeoKumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson Journal: Lancet Oncol Date: 2014-09-16 Impact factor: 41.316
Authors: G Skotnicka-Klonowicz; P Rieske; J Bartkowiak; S Szymik-Kantorowicz; P Daszkiewicz; M Debiec-Rychter Journal: Eur J Surg Oncol Date: 2000-02 Impact factor: 4.424
Authors: Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Peter F Ehrlich; Thomas E Hamilton; Kenneth Gow; Douglas Barnhart; Fernando Ferrer; Jessica Kandel; Richard Glick; Roshni Dasgupta; Arlene Naranjo; Ying He; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Jeffrey S Dome; James Geller; Elizabeth Mullen Journal: Pediatr Blood Cancer Date: 2016-05-27 Impact factor: 3.167
Authors: Tasnim Chagtai; Christina Zill; Linda Dainese; Jenny Wegert; Suvi Savola; Sergey Popov; William Mifsud; Gordan Vujanić; Neil Sebire; Yves Le Bouc; Peter F Ambros; Leo Kager; Maureen J O'Sullivan; Annick Blaise; Christophe Bergeron; Linda Holmquist Mengelbier; David Gisselsson; Marcel Kool; Godelieve A M Tytgat; Marry M van den Heuvel-Eibrink; Norbert Graf; Harm van Tinteren; Aurore Coulomb; Manfred Gessler; Richard Dafydd Williams; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: David B Dix; Conrad V Fernandez; Yueh-Yun Chi; Lindsay A Renfro; Jeffrey S Dome Md Journal: J Clin Oncol Date: 2020-01-17 Impact factor: 44.544
Authors: Jeffrey S Dome; Elizabeth A Mullen; David B Dix; Eric J Gratias; Peter F Ehrlich; Najat C Daw; James I Geller; Murali Chintagumpala; Geetika Khanna; John A Kalapurakal; Lindsay A Renfro; Elizabeth J Perlman; Paul E Grundy; Conrad V Fernandez Journal: J Natl Compr Canc Netw Date: 2021-08-01 Impact factor: 11.908
Authors: Samantha Gadd; Vicki Huff; Andrew D Skol; Lindsay A Renfro; Conrad V Fernandez; Elizabeth A Mullen; Corbin D Jones; Katherine A Hoadley; Kai Lee Yap; Nilsa C Ramirez; Sheena Aris; Quy H Phung; Elizabeth J Perlman Journal: Cell Rep Med Date: 2022-05-25
Authors: Laura M Madanat-Harjuoja; Lindsay A Renfro; Kelly Klega; Brett Tornwall; Aaron R Thorner; Anwesha Nag; David Dix; Jeffrey S Dome; Lisa R Diller; Conrad V Fernandez; Elizabeth A Mullen; Brian D Crompton Journal: J Clin Oncol Date: 2022-05-17 Impact factor: 50.717
Authors: M E Madeleine van der Perk; Nicholas G Cost; Annelies M E Bos; Robert Brannigan; Tanzina Chowdhury; Andrew M Davidoff; Najat C Daw; Jeffrey S Dome; Peter Ehrlich; Norbert Graf; James Geller; John Kalapurakal; Kathleen Kieran; Marcus Malek; Mary F McAleer; Elizabeth Mullen; Luke Pater; Angela Polanco; Rodrigo Romao; Amanda F Saltzman; Amy L Walz; Andrew D Woods; Marry M van den Heuvel-Eibrink; Conrad V Fernandez Journal: Int J Cancer Date: 2022-05-11 Impact factor: 7.316